(Q40621340)
Statements
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer (English)
Cunningham CC
Holmlund JT
Schiller JH
Geary RS
Kwoh TJ
Dorr A